Skip to main content

Advertisement

Table 1 Characteristics of the patients from which samples have been used in this study. nd not determined, PSA prostate-specific antigen

From: Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples

Patients Age Gleason score PSA (ng/mL) Clinical tumoral size: cT Pathological tumoral size: pT Metastatic risk
1 65 6 (3 + 3) 3.7 1 2c Low risk
2 57 6 (3 + 3) 4.38 1 2
3 51 6 (3 + 3) 3.7 2 2
4 49 6 (3 + 3) 4.52 2 2c
5 56 6 (3 + 3) 4.4 2 2c
6 63 7 (3 + 4) 10 1 2c Intermediate risk
7 66 7 (3 + 4) 10 2 2c
8 59 7 (3 + 4) 13 2 2b
9 67 7 (3 + 4) 12.5 1 3a
10 67 7 (3 + 4) 14 1 3a
11 66 7 (3 + 4) 10.4 0 3a
12 55 7 (3 + 4) 13 1 3a
13 56 9 (4 + 5) 26 3 3a High risk
14 63 7 (4 + 3) 25.6 3 3b
15 70 9 (4 + 5) 24.5 2 3b
16 59 8 (4 + 4) 14 2 4
17 48 7 (4 + 3) 14.28 2 3b
18 66 7 (4 + 3) 44 2 3a
19 53 7 (4 + 3) 20 2 3a
20 63 7 (4 + 3) 28 2 nd